Another key milestone for OXC-201 – patent approval in China
Following the recent patent application approval in Japan, the patent for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in China. China and Asia in general are major markets for OXC-201. Asia is estimated to have the largest number of cases of pulmonary fibrosis in the world. Additional national and regional patent applications are pending in the US, Europe (EPO - European Patent Organization) and Canada. As previously communicated, the EIC (European Innovation Council) awarded Oxcia AB in early